Redefining TCRm Safety with ValidaTe
ValidaTe just gave the answer to one of the hardest problems in TCRm-based immunotherapy: how to systematically predict and eliminate off-target toxicity before it kills the program in the clinic.
BioCopy Advances AI Driven Cancer Therapies with Strategic Investment from Haute Capital
As part of a Series A financing round scheduled to close on March 31, 2026, Haute Capital Partners has made a strategic investment in BioCopy
EpiTox: completing our Validate platform for TCR-mimic antibody development
With the publication of EpiTox, all three components of our ValidaTe platform are now publicly validated and available.
EpiPredict: ML-powered identification of pHLA off-targets for TCR-mimic antibodies
EpiPredict delivers a new level of confidence for safety assessment in TCR like drug modalities and provides a powerful solution for developers of T cell receptor mimic (TCRm) antibodies.
Dr. Matthias Wiedenfels discusses BioCopy’s breakthrough AI-powered approach on BioBiz Buzz Podcast
“Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech”
Ranked among Germany’s biotech pioneers of the coming decade
WirtschaftsWoche has selected Matthias Wiedenfels as a winner of “Germany’s 30 by 2030”
BioCopy chooses Genedata for AI-powered Multi-specific Antibody Discovery
Next step towards BioCopys AI-powered high-quality engineering of next-generation cancer therapeutics
BioCopy expands corporate portfolio with acquisition of Perspix Biotech GmbH
Recent company developments across operations, financing, and organizational build out.
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
“Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech”